Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma

Yuzan Kudo; Shiro Kohi; Keiji Hirata; Michael Goggins; Norihiro Sato

doi:10.18632/oncotarget.27172

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma

Yuzan Kudo, Shiro Kohi, Keiji Hirata, Michael Goggins and Norihiro Sato _

PDF | Full Text | How to cite

Oncotarget. 2019; 10:5592-5604. https://doi.org/10.18632/oncotarget.27172

Metrics: PDF 1465 views | Full Text 1701 views | ?

Abstract

Yuzan Kudo1, Shiro Kohi1^,2, Keiji Hirata1, Michael Goggins2 and Norihiro Sato1

1 Department of Surgery 1, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

2 Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Correspondence to:

Norihiro Sato,

email:

[email protected]

Keywords: hyaluronan; synthesis; degradation; pancreatic cancer; prognosis

Abbreviations: PDAC: pancreatic ductal adenocarcinoma; HA: hyaluronan; HAMP: hyaluronan activated-metabolism phenotype

Received: July 04, 2019 Accepted: August 12, 2019 Published: September 24, 2019

ABSTRACT

Background: The aggressiveness of pancreatic ductal adenocarcinoma (PDAC) is enhanced by its interactions with stromal extracellular matrix, notably with hyaluronan (HA). Our previous studies have demonstrated increased expression of genes involved in HA synthesis and degradation in PDAC, suggesting the presence of an autocrine mechanism which accelerates the production of low-molecular-weight HA.

Results: A subset of PDAC (20% of cell lines and 25% of tissues) showed overexpression of multiple genes encoding both HA-synthesizing and HA-degrading enzymes, displaying a phenotype defined as an HA activated-metabolism phenotype (HAMP). Interestingly, HAMP+ cells were more susceptible to the treatment with an HA synthesis inhibitor and HA degradation inhibitor than HAMP- cells. Patients with HAMP+ tumors were significantly associated with shorter survival than those with HAMP- tumors (P = 0.049).

Methods: We investigated transcriptional profiling of genes involved in HA synthesis (including HAS2 and HAS3) and degradation (including HYAL1 and KIAA1199) in a panel of PDAC cell lines and primary tissues. Response of PDAC cells to treatment with an HA synthesis inhibitor (4-methylumbelliferone) or HA degradation inhibitor (dextran sulfate) was examined by cell migration assay. Survival was determined by Kaplan–Meier curve and compared by log-rank test.

Conclusions: The present study identified a novel phenotype, HAMP, characterized by activation of HA metabolism pathways, in PDAC. HAMP should be further investigated as a prognostic marker as well as a target for personalized medicine.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27172

Publication Alerts

Research Papers:

Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma

Abstract